title: Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
abstract: OBJECTIVE
  To evaluate the safety of repifermin (keratinocyte growth factor-2) administered before and after autologous hematopoietic stem cell transplantation (auto-HSCT). A preliminary analysis of the ability of keratinocyte growth factor-2 to prevent mucositis was also done.
  
  
  METHODS
  Forty-two patients received intravenous repifermin (25 microg/kg or 50 microg/kg) or placebo for 3 days before their auto-HSCT conditioning regimen and for up to 10 days after auto-HSCT. Within each dose level, 14 patients were randomized to repifermin and 7 patients to placebo. Clinical evaluations of mucositis were scheduled before auto-HSCT conditioning regimen, on the day of transplant, and three times per week until mucositis resolved.
  
  
  RESULTS
  In general, the incidence of adverse events was similar for patients treated with repifermin and placebo. No clinically meaningful differences were noted among treatment groups for clinical laboratory variables. Treatment groups experienced similar time to engraftment. The frequency of Grade 2 to 4 mucositis was 100% for patients in the placebo group, 64% for patients in the 25 microg/kg group (P = 0.041 versus placebo), and 50% for patients in the 50 microg/kg group (P = 0.006 versus placebo). Results of other endpoints, including pain on swallowing and use of pain medication specifically for mucositis, suggested a better outcome for patients in the 50 microg/kg group compared with the placebo and 25 microg/kg groups.
  
  
  CONCLUSIONS
  Repifermin was well tolerated. Repifermin given before and after auto-HSCT seems to be active in reducing mucositis, but a larger trial will be necessary to determine the efficacy of repifermin with this dose schedule.
authors.affiliation: University of Texas Health Science Center, and South Texas Veterans Health Care System, San Antonio, Texas 78229-3900, USA. reytes@uthscsa.edu
authors.forename: Cesar O
authors.initials: CO
authors.lastname: Freytes
authors.forename: Voravit
authors.initials: V
authors.lastname: Ratanatharathorn
authors.forename: Charles
authors.initials: C
authors.lastname: Taylor
authors.forename: Camille
authors.initials: C
authors.lastname: Abboud
authors.forename: Nancy
authors.initials: N
authors.lastname: Chesser
authors.forename: Alejandro
authors.initials: A
authors.lastname: Restrepo
authors.forename: Jorge
authors.initials: J
authors.lastname: Arango
authors.forename: Daniel
authors.initials: D
authors.lastname: Odenheimer
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D051526:Fibroblast Growth Factor 10; D005346:Fibroblast Growth Factors / Q000008:administration & dosage*; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012449:Safety; D013280:Stomatitis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C496463:FGF10 protein, human; D051526:Fibroblast Growth Factor 10; D010919:Placebos; D005346:Fibroblast Growth Factors